WEST BRIDGEWATER, Mass., Feb. 28 /PRNewswire/ -- Boston Biomedica, Inc. (Nasdaq: BBII) announced today that it will report results for Q4 and FY1999 prior to the market opening on Tuesday, February 29, 2000. Additionally, BBI will conduct a conference call to discuss their results and update investors on the status of the Company's core businesses, their Pressure Cycling Technology (PCT) program, and their Panacos Pharmaceuticals (drug discovery) subsidiary.
The conference call will begin promptly at 11:00 AM (EST) on Tuesday, February 29, 2000. Interested parties may call 1-800-230-1766 at the scheduled time. Please note, that because phone lines are limited, the Company will also offer a live internet broadcast. Visitors may access this call by selecting the Investor Relations link at http://www.bbii.com.
Visitors accessing the call via the internet will require Real Player Software. Users who require this software are encouraged to access the above URL at least 15-30 minutes prior to the scheduled time in order download and install a free version of this software.
The conference call will be available for replay from 1:00 PM, February 29 until 11:59 PM, March 1 by calling 1-800-475-6701, Access Code: 462891. The call will also be archived at the Company's web site. Institutional investors are invited to visit http://www.streetevents.com for both a live and archived version of conference call.
Although the conference call will be held in a listen only-mode, interested parties are invited to e-mail any questions or comments to IR@bbii.com before the call.
Boston Biomedica, Inc. is an infectious diseases management company providing products and services for the detection and treatment of infectious diseases such as AIDS, Lyme Disease, and Viral Hepatitis. The Company has four business units: (1) BBI Diagnostics, an ISO 9001 certified manufacturer and seller of quality control and other diagnostic products used to increase the accuracy of in-vitro diagnostic tests, (2) BBI Clinical Laboratories, a leading specialty infectious diseases testing laboratory, (3) BBI Biotech Research Laboratories, providing R&D support for the other BBI business units as well as contract research services for third parties, and (4) BBI Source Scientific, an ISO 9001 certified manufacturer of laboratory and diagnostic instrumentation. In addition, the Company is pursuing research and development programs in the areas of Pressure Cycling Technology (PCT) and drug discovery (through its wholly owned subsidiary Panacos Pharmaceuticals), with the goal of introducing new solutions for the detection and treatment of infectious diseases.
Statements contained in this news release that state the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future are "forward-looking" statements. It is important to note that the Company's actual results could differ materially from those projected in such forward-looking statements. Factors that could cause actual results to differ from those projected include the possibility that BBI may not be able to release earnings, or that the conference call may not be held, as currently planned. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 1998 and Quarterly Report on Form 10-Q for the quarters ended March 31, June 30 and September 30, 1999. Copies of these documents may be obtained by contacting the Company or the SEC.
Visit us at our web site http://www.bbii.com
Please email us at IR@bbii.com if you prefer to receive future
announcements electronically
SOURCE Boston Biomedica, Inc.
CONTACT: Richard T. Schumacher, CEO and Chairman, or Kevin W. Quinlan, President and COO, William R. Prather, M.D., Sr. VP Finance & Business Dvlp., 508-580-1900, all of Boston Biomedica, Inc.
Web site: www.bbii.com
